Illustrative vial of coronavirus vaccine gettyWhat’s the best way for investors to gain diversified exposure to today's leading vaccine research? Using a diversified strategy to profit from a Covid-19 vaccine makes sense for several reasons:The five leading Covid-19 vaccine developers are shooting for a late 2020 or early 2121 rollout. Johnson & Johnson (JNJ JNJ ) has been in our Portfolio #2, Basic Needs Suppliers for several years — and has been a good performer. Most American have at least one Johnson & Johnson product in their homes. More recently, Johnson & Johnson started a major program to develop a Covid-19 vaccine.

Source: Forbes August 20, 2020 14:26 UTC